CV Therapeutics, Inc. (NASDAQ:CVTX)
20.01
-0 (-0%)
| CV Therapeutics, Inc. (NASDAQ:CVTX) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $20.01 | 52 Week High | $21.15 | ||
| Open | $20.01 | 52 Week Low | $7.06 | ||
| Day High | $20.01 | P/E | N/A | ||
| Day Low | $20.01 | EPS | $-1.61 | ||
| Volume | 825,635 | ||||
| More CVTX Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| GILD | 9 | DNA | 4 |
| GE | 3 | GE | 3 |
| GILD | 3 | DNA | 3 |
| BAC | 3 | BAC | 3 |
| C | 2 | C | 2 |
| DAC | 2 | STLD | 2 |
Entities who have mentioned CVTX
- Citi | View Related Stories »
- JPMorgan | View Related Stories »
- Banc of America | View Related Stories »
- TPG-Axon Capital | View Related Stories »
- UBS | View Related Stories »
- Notable Mergers and Acquisitions | View Related Stories »
- MBA Mortgage Applications | View Related Stories »
- Ben S. Bernanke | View Related Stories »
- Daniel Loeb | View Related Stories »
- Third Point LLC | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Merriman Curhan Ford | View Related Stories »
- Jamie Dimon | View Related Stories »
- New Home Sales | View Related Stories »
- Mortgage Applications | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Piper Jaffray | View Related Stories »
- Deutsche Bank | View Related Stories »
- Standard & Poor's | View Related Stories »
- Dividend | View Related Stories »
- StreetInsider.com Top 10 News Items for the Week | View Related Stories »
- Barclays | View Related Stories »
- Jefferies & Co | View Related Stories »
- Apax Partners | View Related Stories »
- Morgan Joseph | View Related Stories »
View All Major News StreetInsider.com Major News for CVTX
- Gilead Sciences (GILD) to Acquire CV Therapeutics (CVTX) for $20/Share
- CV Therapeutics (CVTX) Reports Large Q4 Loss; Rejects $16 Per Share Bid From Astellas Pharma
View All ReportsStreetInsider.com Reports on CVTX
- Spring Brings 'Green Shoots' For Stocks
- Notable Mergers and Acquisitions of the Day 3/16: BCS, CVTX, BAM
- Astellas Pharma Terminates $16/Sh Offer for CV Therapeutics (CVTX), Clearing Way For Gilead
- Top 10 News Items 3/9-3/13: Stock Stage 4-Day Win Streak; Bank CEOs Make Upbeat Comments (C, JPM, BAC); GE (GE) Gets Rating Cut
- Unusual 11 Mid-Day Movers 3/12: BRNC, CVTX, SEH, MW Higher; MTG, PDII, NP, STLD Lower
StreetInsider Reports on CVTX by Category
View All BlogsBlogs on CVTX
- Fund Clones Q3 2009 Rebalance Update
- Eton Park Loads Up on Options
- Manikay Partners Buy Healthcare, Dump Financials
- Health Care Trends Part 2: M&A, Generic Competition, CROs
- Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly
Comments on CVTX
No comments are currently available.
